Aditya Bardia, MD, MPH, Massachusetts General
Hospital Cancer Center, Harvard Medical School
Circulating tumor cells (CTCs) can serve as potential “liquid biopsies” offering a potential relatively non-invasive tool for monitoring of breast cancer. In partnership with the laboratory of Dr. Mehmet Toner (MGH Center for Bioengineering in Medicine), Dr. Daniel Haber et al. recently developed a nanotechnology micropost-based microfluidic device, the “CTC-ichip”, specifically designed to accurately capture rare and delicate CTCs out of whole blood, following processing through a low shear flow chamber.